The U.S. Food and Drug Administration approved self-administration of AstraZeneca’s asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen.
Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.
The U.S. drug regulator approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women.
EpiPens and other autoinjectors filled with epinephrine to treat severe allergic reactions may still be potent enough to work many months past their labeled expiration date, according to a study that concludes patients might need expensive refills less often.
Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.
Pfizer Inc. received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at the company’s Meridian Medical Technologies site.
Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.
The U.S. Food and Drug Administration extended the expiration date of specific lots of Mylan NV’s EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.
Waltham, Mass.-based AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners, a private equity investment firm.
U.S. FDA Approves Kaléo’s AUVI-Q 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children
Privately held pharmaceutical company kaléo announced that the U.S. Food and Drug Administration approved its supplemental New Drug Application for AUVI-Q (epinephrine injection, USP) 0.1 mg.